4.78
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$4.745
Offen:
$4.67
24-Stunden-Volumen:
2.82M
Relative Volume:
1.16
Marktkapitalisierung:
$368.13M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.9146
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
-14.49%
1M Leistung:
-28.12%
6M Leistung:
-23.76%
1J Leistung:
-48.90%
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ALT
Altimmune Inc
|
4.78 | 368.13M | 409.00K | -101.35M | -71.49M | -1.64 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
2025-01-08 | Eingeleitet | Stifel | Buy |
2024-11-12 | Eingeleitet | UBS | Buy |
2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
2024-01-24 | Eingeleitet | Goldman | Neutral |
2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
2022-12-01 | Eingeleitet | Goldman | Buy |
2021-12-29 | Fortgesetzt | Jefferies | Buy |
2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
2021-02-11 | Eingeleitet | Guggenheim | Buy |
2020-12-14 | Eingeleitet | Jefferies | Buy |
2020-11-12 | Bestätigt | B. Riley Securities | Buy |
2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
2019-07-19 | Eingeleitet | ROTH Capital | Buy |
2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN
PharmAthene stock hits 52-week low at $5.1 amid challenges By Investing.com - Investing.com South Africa
PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo
Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha
Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa
Altimmune rises as buyout rumors follow R&D updates - MSN
Altimmune CFO Gregory Weaver purchases $51,996 in stock By Investing.com - Investing.com Australia
Altimmune Outlines Pemvidutide Plans In MASH And Beyond - insights.citeline.com
Altimmune soars amid takeover speculation - MSN
Altimmune stock rises amid buyout and R&D news(ALT:NASDAQ) - Seeking Alpha
(ALT) Trading Advice - Stock Traders Daily
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Benzinga
Stifel maintains Buy on Altimmune stock, $18 price target - Investing.com India
Stifel maintains Buy on Altimmune stock, $18 price target By Investing.com - Investing.com UK
Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions - TradingView
Altimmune CFO Gregory Weaver purchases $51,996 in stock - Investing.com India
Citizens JMP reiterates Altimmune stock with $25 target By Investing.com - Investing.com South Africa
Citizens JMP reiterates Altimmune stock with $25 target - Investing.com
Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook - TipRanks
Altimmune to test obesity drug for alcohol use disorder and related health conditions - TradingView
Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions - TradingView
Unpartnered Obesity Assets Are Becoming Slim Pickings For Pharma - insights.citeline.com
SBI Securities Co. Ltd. Acquires New Shares in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide - Investing.com Australia
Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com South Africa
Altimmune, Inc. to Host Earnings Call - ACCESS Newswire
Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World
HC Wainwright Has Bearish Estimate for Altimmune Q2 Earnings - Defense World
Altimmune to Host Virtual R&D Day on March 13, 2025 - The Manila Times
Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data - Nasdaq
Can Altimmune's Pemvidutide Transform Both Obesity and MASH Treatment? R&D Day to Reveal Full Potential - StockTitan
Altimmune FY2029 EPS Forecast Decreased by HC Wainwright - Defense World
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):